These results suggested that UTX expression determines the sensitivity of CRC to EZH2 inhibitor, and low UTX expression may serve as a biomarker to identify CRC patients who can benefit from EZH2 inhibitor therapy. The gene discussed is EZH2; the disease is colorectal carcinoma.